SHANGHAI and ROCKVILLE, Md., May 20, 2020 /PRNewswire/ -- I-Mab (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs,... |